Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Aceso Life Science Group Limited
  6. News
  7. Summary
    474   KYG0070S1066


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hao Tian Development : Plans to form Joint Venture to Conduct Research and Develop Cell-based and Biological Therapies for the Treatment of Liver Diseases

07/14/2020 | 05:33am EST

HONG KONG, Jul 14, 2020 - (ACN Newswire) - - Hao Tian Development Group Limited (HKEX Stock Code: 0474, "Hao Tian Development" or "the Group") a diversified investment holding company, through its subsidiary Aceso Life Sciences Holding Limited ("Aceso"), and Promethera Biosciences S.A./N.V. ("Promethera") today announced that the companies have entered into an agreement to form a joint venture ("Joint Venture Company").

Aceso and Promethera hold 60% and 40% of the equity in the Joint Venture Company, respectively. The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialise Promethera's therapeutic products in China and Southeast Asia. Indications in which the products will be deployed include; Acute-on-Chronic Liver Failure (ACLF), Non-Alcoholic Steatohepatitis (NASH), Urea Cycle Disorder (UCD), liver cirrhosis and various autoimmune diseases and cancers. Promethera will manufacture and supply the therapeutic products, and provide ongoing technical support during development and commercialisation. The Joint Venture Company will investigate opportunities for cooperation with Itochu Corporation.

The Asia-Pacific region is home to some of the world's highest liver disease incidence and mortality rates. The number of deaths from liver cirrhosis reached 1.32 million globally in 2017, with China contributing 100,000 deaths and 7 million new patients annually. In addition, in 2018 there were 390,000 new cases of liver cancer in China, along with 370,000 liver cancer deaths, accounting for 47% of global liver cancer deaths. Hao Tian Development has been actively seeking opportunities to expand into the Life Science industry. The formation of the Joint Venture Company and the subsequent introduction of leading global cell therapy and antibody assets for the treatment of a wide variety of diseases in China and Southeast Asia marks a major milestone for the Group

About Promethera Biosciences S.A./N.V.

Promethera Biosciences S.A./N.V. was jointly founded in 2009 by Etienne Sokal, a member of the Belgian Royal Academy of Medicine and a professor at Universite catholique de Louvain (Belgium), and Sopartec S.A., the technology transfer and investment company of Universite catholique de Louvain. Promethera is an innovative biopharmaceutical company primarily focused on developing liver disease cell therapies with the potential to reduce the need for liver transplantation. Promethera's lead product candidate is HepaStem, a patented cell technology with immunomodulatory and anti-fibrotic properties. In addition to cell therapies (HepaStem and H2Stem), Promethera is actively developing an array of antibody-based therapeutics to provide patients with a complete suite of treatments for inflammatory disease and liver disease.

HepaStem is a stem cell biopharmaceutical, derived from healthy, ethically donated livers. The active ingredients of HepaStem are isolated and expanded at Promethera's current Good Manufacturing Practice (cGMP) manufacturing plant. HepaStem's lead indications are Acute-on-Chronic Liver Failure (ACLF), Non-alcoholic Steatohepatitis (NASH) and Urea Cycle Disorder (UCD). In 2019, HepaStem completed a European Phase 2a trial for use in ACLF, which was selected as a breakthrough discovery at the 2019 European Association for the Study of the Liver (EASL). HepaStem is currently being assessed in a potentially pivotal European Phase 2b trial for use in ACLF. Additionally, Promethera is preparing to file an Investigational New Drug (IND) application in order to initiate European clinical trials assessing HepaStem's efficacy in Covid-19 associated Acute Respiratory Distress Syndrome (ARDS).

Promethera's other assets include; (1) H2Stem, a next-generation regenerative medicine derived from hepatobiliary mesenchymal progenitor cells, (2) Novotarg, a pre-clinical stage CD95/CD20 bispecific antibody for the treatment of cancer, and (3) Atrosimab, a pre-clinical stage TNF Receptor 1 monovalent antagonist antibody which will be deployed for the treatment of inflammatory disease and liver disease.

About Aceso Life Science Holding Limited

Aceso Life Science Holding Limited is a joint venture company established by Hao Tian Development Group Limited and Co-High Investment Management Company Limited, who hold 51% and 49% of the joint venture equity, respectively. Aceso Life Science's primary business goal is to introduce leading global life science assets to Greater China and Southeast Asia by acquiring intellectual property and undertaking R&D, distribution and commercialisation.

Copyright 2020 ACN Newswire . All rights reserved.

© Japan Corporate News, source JCN Press Releases

2021Aceso Life Science Group Limited Announces Changes in Composition of the Nomination Com..
2021Aceso Life Science Sees Fiscal H1 Attributable Loss Drop
2021Aceso Life Science Group Limited Reports Earnings Results for the Half Year Ended Septe..
2021Aceso Life Science Group Limited Announces Resignation of Wang Yu as Non-Executive Dire..
2021ACESO LIFE SCIENCE : Selling Stake Worth Nearly $43 Million in Hao Tian International
2021Fong, Tim entered into the Sale and Purchase Agreement to acquire 8.44% stake in Hao Ti..
2021Aceso Life Science Group Limited Announces Executive Changes
2021Aceso Life Science Group Limited Announces Resignation of Li Yao as Non-Executive Direc..
2021Aceso Life Science Group Limited Reports Consolidated Earnings Result for the Year Ende..
2021ACESO LIFE SCIENCE : Supplemental joint announcement discloseable transaction in relation ..
More news
Sales 2021 98,0 M 12,6 M 12,6 M
Net income 2021 -376 M -48,3 M -48,3 M
Net Debt 2021 2 086 M 268 M 268 M
P/E ratio 2021 -3,59x
Yield 2021 -
Capitalization 1 322 M 170 M 170 M
EV / Sales 2020 -120x
EV / Sales 2021 37,3x
Nbr of Employees 167
Free-Float 37,2%
Duration : Period :
Aceso Life Science Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACESO LIFE SCIENCE GROUP LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Chi Tak Fok Chief Financial Officer & Executive Director
Ming Sun Chan Independent Non-Executive Director
Kwan Sing Lam Independent Non-Executive Director
Yiu Tong Mak Independent Non-Executive Director
Hai Ying Xu Executive Director
Sector and Competitors